hVIVO (LON:HVO) Stock Price Down 4.1% – Should You Sell?

hVIVO plc (LON:HVO) dropped 4.1% on Tuesday . The company traded as low as GBX 6.80 ($0.09) and last traded at GBX 7 ($0.09). Approximately 4,704,116 shares were traded during trading, an increase of 61% from the average daily volume of 2,922,295 shares. The stock had previously closed at GBX 7.30 ($0.10).

Analysts Set New Price Targets

A number of research firms have recently weighed in on HVO. Peel Hunt reiterated an “add” rating and set a GBX 21 target price on shares of hVIVO in a research report on Tuesday, July 29th. Shore Capital cut their target price on shares of hVIVO from GBX 35 to GBX 25 and set a “buy” rating on the stock in a research report on Tuesday, September 23rd. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, hVIVO presently has a consensus rating of “Buy” and a consensus price target of GBX 23.

hVIVO Trading Down 4.9%

The company has a market capitalization of £45.08 million, a P/E ratio of 851.95 and a beta of 0.97. The business has a fifty day moving average of GBX 9.56 and a 200-day moving average of GBX 12.24. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61.

hVIVO (LON:HVO) last released its quarterly earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.